A high-dose influenza vaccine reduces the risk of death and incidence of hospitalization for influenza and pneumonia among older adults.
A high-dose influenza vaccine is associated with a reduction in the risk of death and in the incidence of hospitalization for influenza or pneumonia in older adults compared with standard-dose vaccinations, according to data presented at the European Society of Cardiology Congress 2022.
Risk of death was reduced by 49% and hospitalization incidence was reduced by 64% in the pragmatic randomized trial. Previous research found contracting influenza increased the risk of myocardial infarction by 6-fold in the week after and that 19% of heart failure hospitalizations could be attributed to influenza during the months with high influenza activity. Other research indicated vaccination against influenza prevents cardiovascular events.
“The reductions in hospitalizations and all-cause mortality with the high-dose vaccine were encouraging but require confirmation in a larger trial before potentially guiding clinical practice,” senior author and chief investigator Tor Biering-Sørensen, MD, PhD, MPH, of the Centre for Translational Cardiology and Pragmatic Randomised Trials at the University of Copenhagen in Denmark, said in a statement.
While most countries have approved high-dose influenza vaccines for adults 60 years and older, only a few countries offer this vaccine by default for older adults. As a result, high-dose vaccines are not widely used despite evidence that they provide additional protection compared with standard-dose vaccines, Biering-Sørensen said.
Standard-dose vaccines contain 15 μg of haemagglutinin antigen for each strain compared with high-dose vaccines which contain 60 μg.
The DANFLU-1 study integrated a pragmatic randomized trial into the official Danish vaccination program with a central trial site at a public university hospital and more than 1000 vaccination sessions across the country. It was an open-label study randomizing patients 1:1 to either high-dose or standard-dose quadrivalent influenza vaccine. While the primary objective was to evaluate the feasibility of the trial design, the secondary objective was to estimate the relative effectiveness of the high-dose vaccine.
Participants were between the ages of 65 and 79 years. Overall, 12,477 were included in the final analysis (6245 high-dose and 6232 standard-dose). The average age was 71.7 years and 47.1% were women.
Incidence of hospitalizations for influenza or pneumonia was lower for participants who received the high-dose vaccine compared with those who had the standard dose (10 vs 28 events, respectively). Individuals who received the high-dose vaccine also had a lower incidence of all-cause mortality (21 vs 41 events). Serious adverse events between the 2 groups were similar.
“Conducting an innovative pragmatic randomized trial in Denmark using administrative health registries as the primary data source was feasible,” Biering-Sørensen said. “Integrating an influenza vaccine trial into the official Danish vaccination program was also feasible. The next step is to conduct a fully powered trial of high-dose versus standard-dose quadrivalent influenza vaccine in older adults. The required sample size is expected to be around 200,000 participants.”
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More